Clinical trial · Observational
A Chinese Cohort of Cervical Large Cell Neuroendocrine Carcinoma
Clinical Characteristics and Prognostic Factors of Large Cell Neuroendocrine Carcinoma of the Cervix: A Multicenter, Bidirectional Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cervical large cell neuroendocrine carcinoma (LCNEC) exhibits highly aggressive biological behavior, including strong invasiveness, a high propensity for metastasis, drug resistance, and poor prognosis, necessitating heightened clinical and pathological awareness. This study aims to summarize the clinical characteristics of LCNEC and analyze various prognostic factors to enhance understanding and vigilance toward this disease. Combined with precise pathological diagnosis, improving diagnostic accuracy is crucial for formulating treatment strategies and assessing patient prognosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Cervical Neoplasms | Cervical Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Postoperative pathological examination confirmed cervical large cell neuroendocrine carcinoma. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cervical Large Cell Neuroendocrine Carcinoma Cohort
- interventionNames
- Other: Postoperative pathological examination confirmed cervical large cell neuroendocrine carcinoma.
Primary outcomes (2)
- measure
- Overall Survival
- timeFrame
- One month post-enrollment completion and then annual follow-up
- measure
- Disease Recurrence
- timeFrame
- One month post-enrollment completion and then annual follow-up
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: The diagnosis of cervical large cell neuroendocrine carcinoma (LCNEC) was confirmed by histopathological examination, meeting both clinical and histological criteria. The tumor exhibited characteristic features, including large cells with abundant cytoplasm, vesicular nuclei with prominent nucleoli, and a high mitotic rate (\>10 mitoses/10 HPFs). The growth patterns were predominantly insular, trabecular, or solid, often accompanied by peripheral palisading or rosette formation, along with focal tumor necrosis. \- Exclusion Criteria: Mixed cervical LCNEC histology, cases with missing follow-up, or patients lost to contact. \-
References
Publications (6)
- BACKGROUNDTakayanagi D, Hirose S, Kuno I, Asami Y, Murakami N, Matsuda M, Shimada Y, Sunami K, Komatsu M, Hamamoto R, Kato MK, Matsumoto K, Kohno T, Kato T, Shiraishi K, Yoshida H. Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix. Cancers (Basel). 2021 Mar 10;13(6):1215. doi: 10.3390/cancers13061215. PMID 33802174
- BACKGROUNDGeorgescu TA, Bohiltea RE, Munteanu O, Furtunescu F, Lisievici AC, Grigoriu C, Gherghiceanu F, Vladareanu EM, Berceanu C, Ducu I, Iordache AM. Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract. Medicina (Kaunas). 2021 Dec 7;57(12):1338. doi: 10.3390/medicina57121338. PMID 34946283
- BACKGROUNDXu F, Yu Q, Wan D, Zhang Y. Cervical adenocarcinoma admixing with large cell neuroendocrine carcinoma: A rare case report. Asian J Surg. 2022 Dec;45(12):2932-2933. doi: 10.1016/j.asjsur.2022.06.109. Epub 2022 Jun 29. No abstract available. PMID 35778245
- BACKGROUNDSalvo G, Gonzalez Martin A, Gonzales NR, Frumovitz M. Updates and management algorithm for neuroendocrine tumors of the uterine cervix. Int J Gynecol Cancer. 2019 Jul;29(6):986-995. doi: 10.1136/ijgc-2019-000504. PMID 31263021
- BACKGROUNDLee E, Ji YI. Large Cell Neuroendocrine Carcinoma of the Cervix with Sequential Metastasis to Different Sites: A Case Report. Case Rep Oncol. 2018 Oct 23;11(3):665-670. doi: 10.1159/000493912. eCollection 2018 Sep-Dec. PMID 30483095
- BACKGROUNDCaruso G, Sassu CM, Tomao F, Di Donato V, Perniola G, Fischetti M, Benedetti Panici P, Palaia I. The puzzle of gynecologic neuroendocrine carcinomas: State of the art and future directions. Crit Rev Oncol Hematol. 2021 Jun;162:103344. doi: 10.1016/j.critrevonc.2021.103344. Epub 2021 Apr 29. PMID 33933568